Entera Bio (ENTX) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
ProKidney is the larger company by market cap ($626.7 million vs $436.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ENTX | PROK |
|---|---|---|
| Share price | $2.51 | $1.57 |
| Market cap | $436.32M | $626.72M |
| 1-day change | -0.79% | -1.87% |
| YTD return | +29.38% | — |
| 1-year return | +32.80% | — |
| 5-year return | -44.47% | — |
| EPS (TTM) | $-0.36 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $3.48 |
| 52-week low | $0.91 | $1.30 |
| Distance from 52-week high | -40.24% | -54.89% |
| Average volume | 1.81M | 1.31M |
| Shares outstanding | 173.83M | 208.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ENTX vs PROK FAQ
Which is bigger, Entera Bio or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $626.72M compared with $436.32M for Entera Bio (ENTX).
Are Entera Bio and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.